On the Influence of Fabrication Methods and Materials for mRNA-LNP Production: From Size and Morphology to Internal Structure and mRNA Delivery Performance In Vitro and In Vivo.

LNP internal structure PEGylated lipids mRNA delivery microfluidics polysarcosine

Journal

Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613

Informations de publication

Date de publication:
18 Jun 2024
Historique:
revised: 13 06 2024
received: 15 04 2024
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 18 6 2024
Statut: aheadofprint

Résumé

Lipid nanoparticle (LNP) remains the most advanced platform for messenger RNA (mRNA) delivery. To date, mRNA LNPs synthesis is mostly performed by mixing lipids and mRNA with microfluidics. In this study, we developed a cost-effective microfluidics for synthesizing mRNA LNPs. It allows to fine-tune the LNPs characteristics without compromising LNP properties. We compared it with a commercial device (NanoAssemblr) and ethanol injection and investigated the influence of manufacturing conditions on the performance of mRNA LNPs. LNPs prepared by ethanol injection exhibited broader size distributions and more inhomogeneous internal structure (e.g., bleb-like substructures), while other LNPs showed uniform structures with dense cores. Small angel X-ray scattering (SAXS) data indicate a tighter interaction between mRNA and lipids within LNPs synthesized by custom device, compared to LNPs produced by NanoAssemblr. Moreover, the better transfection efficiency of polysarcosine (pSar)-modified LNPs may be attributed to a higher surface roughness than that of PEGylated LNPs. The manufacturing approach showed modest influence on mRNA expression in vivo. In summary, the home-developed cost-effective microfluidic device can synthesize LNPs and represents a potent alternative to NanoAssemblr. The preparation methods showed notable effect on LNPs' structure but a minor influence on mRNA delivery in vitro and in vivo. This article is protected by copyright. All rights reserved.

Identifiants

pubmed: 38889433
doi: 10.1002/adhm.202401252
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2401252

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Dongdong Bi (D)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Christoph Wilhelmy (C)

Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.

Dennis Unthan (D)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Isabell Sofia Keil (IS)

TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, 55131, Mainz, Germany.

Bonan Zhao (B)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Bastian Kolb (B)

Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.

Roman I Koning (RI)

Electron Microscopy Facility, Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, 2300 RC, The Netherlands.

Melissa A Graewert (MA)

European Molecular Biology Laboratory (EMBL) Hamburg Outstation c/o DESY, 22607, Hamburg, Germany.

Bert Wouters (B)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Raphaël Zwier (R)

Leiden Institute of Physics Research, Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Jeroen Bussmann (J)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Thomas Hankemeier (T)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Mustafa Diken (M)

TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, 55131, Mainz, Germany.

Heinrich Haas (H)

Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.

Peter Langguth (P)

Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.

Matthias Barz (M)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.
Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

Heyang Zhang (H)

Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.

Classifications MeSH